^
    1d
    Clinical perception and novel insights of chronic myelomonocytic leukemia: a 10-year multi-center retrospective study. (PubMed, Front Med (Lausanne))
    Although chemotherapy can induce remission in some cases, long-term survival remains limited. The enrollment in clinical trials should be encouraged to improve patient prognosis.
    Retrospective data • Journal
    |
    B2M (Beta-2-microglobulin)
    6d
    NCI-2016-01233: Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, University of Southern California | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Tecentriq (atezolizumab) • guadecitabine (SGI-110)
    6d
    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov)
    P=N/A, N=153, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Valcyte (valganciclovir)
    8d
    PRT2527-02: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies (clinicaltrials.gov)
    P1, N=86, Completed, Prelude Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • PRT2527
    8d
    CONCERTO: Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, University of Utah | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCR (BCR Activator Of RhoGEF And GTPase) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11)
    |
    BRAF mutation
    |
    Cotellic (cobimetinib)
    9d
    Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia. (PubMed, Blood Cancer Discov)
    We developed a weighted genomic model and diagnostic workflow showing that combining genomic signatures with bone marrow monocyte frequencies in OM-CMML more accurately predicts progression to overt CMML. These findings support integrating genomic determinants, and our clinic-ready diagnostic workflow, into the CMML diagnostic framework to improve accuracy.
    Journal
    |
    TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2)
    |
    TET2 mutation • SRSF2 mutation
    11d
    Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML (clinicaltrials.gov)
    P1, N=32, Completed, Newave Pharmaceutical Inc | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Dec 2025 | Trial primary completion date: Jan 2025 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    azacitidine • lacutoclax (LP-108)
    13d
    Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P1/2, N=64, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    decitabine • Elzonris (tagraxofusp-erzs)
    22d
    Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine
    27d
    P-TRP-2447-14: Hu8F4 in Treating Patients With Advanced Hematologic Malignancies (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    Hu8F4
    28d
    Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML (clinicaltrials.gov)
    P=N/A, N=224, Active, not recruiting, Guangdong Provincial People's Hospital
    New trial
    |
    Venclexta (venetoclax) • azacitidine
    29d
    Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) (clinicaltrials.gov)
    P1/2, N=66, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • Niktimvo (axatilimab-csfr)